BeiGene Corporate Presentation

May 4, 2023

Disclosures

Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeiGene's research, discovery, and pre-clinical and early-stage clinical programs and plans; recent clinical data for BeiGene's product candidates and approvals of its medicines; the conduct of late-stage clinical trials and expected data readouts; additional planned commercial product launches; and the advancement of and anticipated clinical development, regulatory milestones and commercialization of BeiGene's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGene's clinical development, commercial, regulatory and other operations, as well as those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.

Some of the clinical data in this presentation relating to BeiGene's investigational drug candidates is from pre-clinical studies or early phase, single-arm clinical trials. When such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentation and discussion are not based on head-to-head trials between BeiGene's investigational drug candidates and other products unless specified in the trial protocol. BeiGene is still conducting pre-clinical studies and clinical trials and, as additional patients are enrolled and evaluated, data on BeiGene's investigational drug candidates may change.

This presentation and the accompanying oral presentation contain data and information obtained from third-party studies and internal company analysis of such data and information. BeiGene has not independently verified the data and information obtained from these sources. Forward-looking information obtained from these sources is subject to the same qualifications noted above.

BeiGene

Founded
2010

@BeiGeneGlobal BeiGene

Numbers as of March 2023

~40 offices, **9,400+** colleagues on **5** continents

$1.3B in annual product revenue
$3.8B cash balance*

3,500+ global commercial team
16 approved products

950+ oncology research team

2,700 global clinical development & medical affairs team

In-house manufacturing plus U.S. expansion under construction

60+ pre-clinical programs, the majority with first-in-class potential

~50 assets in clinical and commercial stages

~20 industry collaborations

Building Strategic and Sustainable Competitive Advantages

Innovation with speed and lower cost to better serve patients around the world

Our Five Sustainable Competitive Advantages:

1 Research

- 950+ research team with entrepreneurial culture
- Heme, solid tumor and I&I franchise including 60+ preclinical programs, ~50% with first-in-class potential
- Focus on innovative modalities in oncology and I&I

2 Clinical Dev

- Cost and time-advantaged clin dev
- 2,300 clinical development colleagues
- Global development, Asia inclusive (45+ geographies)
- ~50 assets in clin & comm stage
- 20,000+ subjects enrolled

3 Commercial

- 3,300+ in China including medical affairs, competitively positioned, science-based leadership
- 500+ competitive footprint in North America & Europe
- Expanding presence in multiple countries/ regions, including underserved areas

4 Cornerstone Med

- Cornerstone commercial medicines with huge global potential, BTKi and PD-1
- Complemented by deep and innovative clinical portfolio

5 Manufacturing

- 500+ people in 3 mfg. sites; In-house capabilities bring cost, agility to internal and external programs
  - Suzhou
  - Guangzhou
  - Hopewell, NJ
- Capability to manufacture both small molecules and biologics

TRANSLATING SCIENCE TO IMPROVE ACCESS AND AFFORDABILITY BY CHALLENGING THE STATUS QUO

Trials Span

45+

Countries & Regions

20K+

People Enrolled in

110+

Clinical Trials



Positioned to Deliver on Significant Revenue Growth

Key Drivers

- Significant revenue growth driven by BRUKINSA
- Growing share of PD1/L1 class in China, expanding top leadership position
- Continued revenue growth for partner medicines
- Execution of commercial launches for late-stage pipeline
- Continued global commercial expansion

Differentiated Biological Hypothesis and First-in-Class Programs Based on Deep Oncology Insights from the Bench

- **BTK -** Higher exposure, better selectivity, targeted inhibition
- **PD-1 -** Fc function silenced
- **TIGIT -** Intact Fc function, first wave
- **BCL2 -** Higher potency, increased selectivity, and shorter half life
- **BTK Degrader -** Potentially first-in-class, eliminates both kinase and non-kinase function of BTK, should inhibit BTKi resistant strains
- **OX-40 -** Only OX-40 Ab not interfering with OX-40 ligand binding
- **HPK-1 -** Potentially first-in-class intracellular checkpoint inhibitor
- **CEA-41BB -** Potentially first-in-class immune activator, converting immune cold tumor to hot

Differentiated biological hypothesis

Potential first-in-class, or first wave

Productive Research and Path to Global Oncology Leadership



Prolific First Decade

2013 - 2015

BRAF
PARP*
BTK*
PD-1*

2016 - 2020

TIM-3
TIGIT
BCL-2
OX40
PI3Kd

Entering a New Era of Discovery

2021-2023

HPK-1
TYK2
SMAC mimetic
BTK-Targeted CDAC
CEA x 4-1BB bispecific

4+ NMEs in 2023

SM and mAb: 20+ New programs
ADC: 10+ TAAs
Pro-Cytokine

2024+

10 New Molecules in the Clinic Expected Annually

CDAC: Total 7+ programs
BsAb/TsAb: 10 new programs
mRNA Therapy

Cell therapy: CAR-NK and more

*Approved 2019-2021

SM, Small Molecule; mAb, Monoclonal Antibody; ADC, Antibody Drug Conjugate; TAA, Tumor Associated Antigen; CDAC, Chimeric Degradation Activating Compound (targeted protein degradation); BsAb, Bispecific Antibody; TsAb, Trispecific Antibody; CAR-NK, Chimeric Antigen Receptor-Natural Killer Cell, NME, New Molecular Entity

Oncology Research Expertise With Proven Track Record of Innovation

Research Team Expansion

Science-driven culture from inception

Prolific in first decade and expected to be more productive in the years ahead

- **60+** preclinical programs, **~50%** with first-in-class or best-in-class potential
- A burst of new clinical molecules expected in the next few years, 10+ INDs per year expected starting in 2024

Expanding new capabilities and talent base with intent to expand into the US

- **Invest in new modalities** including CDAC, BsAb / TsAb, ADC, NK cell therapies, pro-cytokines
- Investing in new capabilities and driving efficiencies through portfolio management

Quality validated by clinical results, global approvals, and major pharma/biotech partnerships that have generated $1.4bn collaboration fees

Global Research Headcount

Highly productive 950+ scientists

- Low-cost and high-efficiency
- Quality validated by clinical results and global partnerships
- Expertise across multiple scientific disciplines



BRUKINSA Superiority to Ibrutinib Core to Hematology Franchise*

Brukinsa® zanubrutinib 80mg capsules

Best-in-Class Hypothesis

- Complete and sustained target inhibition in disease originating tissues
- Maintains therapeutic concentrations over 24 hours
- Equally or more selective than any approved BTKi

Broad Global Clinical Program

4,900+ Subjects

- **35** trials across **29** markets
- Two head-to-head studies versus ibrutinib – 800+ subjects
- Comprehensive label vs. next generation BTKi (approved in CLL, MCL, WM, MZL)

Demonstrating Clinical Advantages

- First and only BTKi to demonstrate superior efficacy versus ibrutinib – ORR and PFS
- Favorable safety versus ibrutinib with improved cardiac profile - Afib, and 0% vs 1.9% sudden cardiac death in ALPINE
- Dosing flexibility – QD / BID

*Superior to ibrutinib in ORR & PFS for R/R CLL in ALPINE trial.

ALPINE: BRUKINSA PFS & ORR Superiority to Ibrutinib in R/R CLL/SLL 2022 ASH Late Breaker & Concurrent NEJM Manuscript

BRUKINSA PFS by IRC Significantly Superior to Ibrutinib



BRUKINSA Improved PFS in Patients with del(17p)/*TP53*^{mut}



Data cutoff: 8 Aug 2022. Brown J et al. NEJM 2022. DOI: 10.1056/NEJMoa2211582

BRUKINSA: Establishing Leadership with Best-In-Class BTKi

BRUKINSA Global Revenues



- BTKi is the cornerstone therapy and the standard of care for non-Hodgkin's lymphoma
- The BTKi market was $8.4bn in 2022
- CLL is the largest indication for BTKi, accounting for 80% of the market
- Given its best-in-class profile, as demonstrated in head-to-head clinical trials for CLL, BRUKINSA is well positioned to become the leading BTKi

Successful approvals in CLL are unlocking BRUKINSA's value globally and anticipated to drive revenue growth

Tislelizumab Well Positioned for Global Success

1 Mechanistically differentiated, Fc-γ receptor sparing, and multiple combinations under study

2 Realizing Impact from favorable labels and NRDL coverage in China

- Achieved #1 value market share in China despite late to market; future filings in ROW

3 Broad clinical program, including:

- **21** registration-enabling clinical trials
- **12,100+** subjects enrolled in clinical trials in **30+** countries and regions, with **4,000+** from outside of China

4 Commitment to quality, global manufacturing

- Built state-of-the-art facility in Guangzhou, building toward 200,000L of biologics capacity
- Collaboration with one of the world's leading biologics manufacturers

Boehringer Ingelheim | **25 global biologics manufacturing approvals**

5 Future global approvals in more indications, and combinations

- 10 approved indications in China: R/R cHL, R/R UC, 1L Sq, 1L non-Sq NSCLC, 2L/3L HCC and 2L/3L NSCLC, 2L/3L MSI-H or dMMR solid tumors, 2L ESCC, 1L NPC, 1L G/GEJ
- 1 filing in the U.S.: 2L ESCC*, 2 filings in Europe: NSCLC & ESCC, filings in Australia and UK in NSCLC & 2L ESCC, and 2 in China in 1L ESCC & 1L HCC.
- 11 other pivotal or potentially registration-enabling studies ongoing; compelling breadth of combinations e.g., ociperlimab, sitravatinib, zanidatamab, etc.
- IO combination trials underway to drive success

Collaboration with Novartis

- Acceleration of global development in Novartis territory: North America, Europe, and Japan
- Further explore combination opportunities with Novartis pipeline
- Eligible for up to $1.5 billion collaboration revenue from Novartis

*Subject to regulatory inspections which have been delayed due to COVID-19 travel restrictions. cHL = classical Hodgkin's lymphoma; CR = complete response; dMMR = Deficient Mismatch Repair; ESCC = Esophageal Squamous-Cell Carcinoma; HCC = hepato-cellular carcinoma; MSI-H = microsatellite instability-high; NRDL = China National Reimbursement Drug List; non-Sq: non-squamous; NPC = Nasopharyngeal carcinoma; NSCLC = non-small cell lung cancer; R/R = relapsed/refractory; UC = urothelial carcinoma

BeiGene's Internal Discovery Pipeline



*Some indications will not require a non-pivotal Phase 2 clinical trial prior to beginning pivotal Phase 2 or 3 clinical trials; **Confirmatory clinical trials post-approval are required for accelerated approvals; † Novartis owns commercial rights in United States, Canada, Mexico, the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. ^SMAC = second mitochondrial-derived activator of caspase. # single-country trial. 1. BGB-3111-215 trial in previously treated B-cell lymphomas intolerant of prior BTKi treatment. 2. In collaboration with SpringWorks Therapeutics. 3. Developed by MapKure, LLC, jointly owned by BeiGene and SpringWorks. MapKure and is currently developing BGB-3245 under an exclusive license from BeiGene.

BeiGene

BCL-2i Program Summary

- BGB-11417 is a BCL2 inhibitor with potential to be best in class given higher potency and increased selectivity as well as shorter half-life compared to venetoclax that can potentially lead to improved efficacy and safety.
- Broad development plan initiated in CLL, NHL (including WM, MCL, MZL), AML, MDS and MM.
- With 400+ patients treated to date in 4 phase 1 studies, no safety concerns.
- Encouraging early efficacy in all indications eg. durable and deep responses seen in CLL at all doses tested- longer follow up is needed for higher dose. AML patients on BGB-11417 + azacitidine have high rates of blast clearance with doses as low as 40mg and responses are durable.
- Two trials with registrational intent:
  - **R/R MCL** after failure of BTKi
  - **R/R CLL** after failure of BTKi
- Broad registrational opportunities

BGB-16673: BTK Chimeric Degradation Activating Compound for B-Cell Malignancies Showing Promise in Clinic

- Targeting BTK via an alternative mechanism
- **New generation** BTK inhibitor to enhance BTK expertise
  - To overcome BTK kinase inhibitor resistance
  - To destroy non-kinase (scaffolding) function
- **BGB-16673**, BeiGene's first CDAC molecule advanced to clinic
  - **2.5 years from program initiation to clinic**
  - Good pharmacological properties
    - No IMiD activity
    - Highly potent and selective
    - Good oral bioavailability and long $t_{1/2}$
  - **Complete BTK degradation and clinical response observed at the first dose level**, 50 mg

Deep, Rapid & Sustainable BTK Degradation Observed at the First Dose Level in Phase 1 Study (50 mg)



BGB-16673 can Overcome both Zanubrutinib and LOXO-305 Resistance



IMiD: immunomodulatory imide drug

Clinical Pipeline from External Collaboration

Program / indication	P1a	P1b	P2*	P2**	P3	Filed	Commercial rights	Partner
Sitravatinib[a] ***(multi-kinase inhibitor)*** - 2/3L NSCLC (+ tislelizumab)							Asia ex-Japan, AU, NZ	Mirati
Sitravatinib[a] - HCC#, GC/GEJC# , 2/3L ESCC# (Mono, + tislelizumab)							Asia ex-Japan, AU, NZ	Mirati
Sitravatinib[a] - Solid Tumors (Mono, + tislelizumab)							Asia ex-Japan, AU, NZ	Mirati
Zanidatamab[b] ***(HER2, bispecific antibody)*** - 1L HER2+ GEA (+ chemo ± tislelizumab)							Asia ex-Japan, AU, NZ	Zymeworks
Zanidatamab[b] - Biliary tract cancers (Mono)							Asia ex-Japan, AU, NZ	Zymeworks
ZW49 ***(HER2, bispecific ADC)*** - HER2-expressing cancers							Asia ex-Japan, AU, NZ	Zymeworks
LBL007 ***(LAG-3)*** - Solid Tumors (+ tislelizumab)							Ex-China	Nanjing Leads Biolabs
SEA-CD70 ***(anti-CD70)*** - MDS, AML							Asia ex-Japan, AU, NZ	Seagen
AMG 176 ***(Mcl- 1)*** - Hematologic malignancies							China	Amgen
Sotorasib ***(KRAS G12C)*** - Solid tumors, CRC, NSCLC							China	Amgen
Tarlatamab[c] ***(DLL3 x CD3)*** – SCLC, Neuroendocrine Prostate Cancer[1]							China	Amgen
AMG 509 ***(STEAP 1 x CD3)*** - Prostate cancer							China	Amgen
AMG 199[c] ***(MUC17 x CD3)*** - GC/GEJC, Colorectal, and Pancreatic Cancers							China	Amgen
Acapatamab[c] ***(PSMA x CD3)*** - Prostate cancer, NSCLC							China	Amgen
AMG 256 ***(Anti-PD-1 x IL21 mutein)*** - Solid tumors							China	Amgen
ABI-H3733 ***(HBV core inhibitor)*** - Chronic Hepatitis B virus							Greater China	Assembly Bio

Heme | Solid Tumor | Non-oncology

a. Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non-Sq NSCLC; b. ZW25; c. Half-life extended BiTE® molecule; # single-country trial. *Some indications will not require a non-pivotal Phase 2 clinical trial prior to beginning pivotal Phase 2 or 3 clinical trials; **Confirmatory clinical trials post-approval are required for accelerated approvals. 1. This is a Phase 1 trial.

BeiGene

Growing Commercial Portfolio: 16 Approved Assets

Product	Lead Indications	Mechanism of Action	Regulatory Status	Our Commercial Rights	Partner
Brukinsa® zanubrutinib	U.S.: CLL,R/R MCL[1], WM & R/R MZL[1]; China: R/R MCL[2], R/R CLL/SLL[2] & R/R WM[2]; EU[3]: CLL, WM & MZL	BTK inhibitor	Approved in more than 65 markets, incl. U.S., China, EU and other markets	Global	NA
Tislelizumab	China:1L Squamous and Non-Squamous NSCLC, 2/3 L NSCLC, R/R classical Hodgkin's lymphoma[2], 2/3 L HCC[2], R/R PD-L1+ UC[2], 2L ESCC, MSI-H or dMMR solid tumors[2], 1L NPC, 1L G/GEJ	Anti-PD-1 antibody	Approved in China BLA Accepted in U.S.[4] MAA accepted in EU[4]	Outside North America, Japan, UK, AU, EU and six other European countries	NOVARTIS
pamiparib	3L BRCA-mutated ovarian cancer[2]	PARP Inhibitor	Approved in China	Global	BeiGene
XGEVA® (denosumab)	Giant cell tumor of bone[8], Skeletal Related Events (SREs)[7]	Anti-RANK ligand antibody	Approved in China	Mainland China	AMGEN®
BLINCYTO® (blinatumomab)	R/R Acute lymphocytic leukemia[7]	Anti-CD19 x anti-CD3 bispecific T-cell engager (BiTE®)	Approved in China	Mainland China	AMGEN®
Kyprolis® (carfilzomib)	R/R Multiple myeloma[7]	Proteasome inhibitor	Approved in China	Mainland China	AMGEN®
Revlimid® (lenalidomide)	R/R adult multiple myeloma, newly diagnosed multiple myeloma, previously treated follicular lymphoma	Anti-angiogenesis, immuno-modulation	Approved in China	Mainland China	Bristol Myers Squibb™
Vidaza® azacitidine	Myelodysplastic syndromes, acute myeloid leukemia, chronic myelomonocytic leukemia	DNA hypomethylation	Approved in China	Mainland China	Bristol Myers Squibb™
sylvant® siltuximab	Idiopathic multicentric Castleman disease	IL-6 antagonist	Approved in China	Greater China	EUSAPharma
Qarziba® ▼	High-risk neuroblastoma[2]	Anti-GD2 antibody	Approved in China	Mainland China	EUSAPharma

1. Approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 2. Conditionally approved. Full approval for these indications is contingent upon results from ongoing randomized, controlled confirmatory clinical trials. 3. The approval is applicable to all 27 EU member states, plus Iceland, Lichtenstein and Norway. 4. U.S.: For patients with unresectable recurrent locally advanced or metastatic ESCC after prior systemic therapy. EU: For patients with advanced or metastatic ESCC after prior systemic chemotherapy and for patients with NSCLC including: locally advanced or metastatic NSCLC after prior chemo, in combination with chemotherapy for 1L advanced or metastatic squamous NSCLC, and in combination with chemotherapy for 1L locally advanced or metastatic non-squamous NSCLC with no EGFR or ALK positive mutattions.

Growing Commercial Portfolio
WITH 16 APPROVED ASSETS

PRODUCT	LEAD INDICATIONS	MECHANISM OF ACTION	REGULATORY STATUS	OUR COMMERCIAL RIGHTS	PARTNER
POBEVCY® (Avastin biosimilar)	Colorectal, lung, glioblastoma, ovarian, and cervical cancers	Anti-VEGF antibody	Approved in China	Greater China	百奥泰 BIO-THERA
TAFINLAR® (dabrafenib)	Melanoma and BRAF V600 Mutation NSCLC	BRAF inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
MEKINIST® (trametinib)	Melanoma and BRAF V600 Mutation NSCLC	MEK inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
VOTRIENT® (pazopanib)	Advance renal cell carcinoma	VEGFR inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
AFINITOR® (everolimus)	Advance renal cell carcinoma[5], NET, SEGA and Breast cancer	mTOR inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
ZYKADIA® (ceritinib)	ALK + NSCLC	ALK inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS

5. Following progression on or after vascular endothelial growth factor (VEGF)-targeted therapy. 6. Rights to promote and market in China's broad markets pursuant to a Market Development Agreement with an affiliate of Novartis Pharma AG. 7. Conditionally approved. Full approval of any particular indication will depend on the results of required post-marketing study(ies) in China

Abbreviations: ALK = anaplastic lymphoma kinase; BLA = Biologics License Application; BRAF = B-rapidly accelerated fibrosarcoma; CLL = chronic lymphocytic leukemia; HCC = hepatocellular carcinoma; MCL = mantle cell lymphoma; MEK = mitogen-activated protein kinase (MAPK) / Extracellular-signal regulated kinase (ERK); MSI = microsatellite instability-high; mTOR = Mammalian target of rapamycin; MZL = marginal zone lymphoma; NET = Neuroendocrine tumors; NPC = nasopharyngeal carcinoma; NSCLC = non-small cell lung cancer; R/R = relapsed / refractory; SEGA = subependymal giant cell astrocytomas; SLL = small lymphocytic lymphoma; UC = urothelial carcinoma; VEGFR = vascular endothelial growth factor receptor; WM = Waldenström's macroglobulinemia

Growing Commercial Revenue Stream





We Work Collaboratively with Our Partners, Large and Small, Regionally and Globally, to Provide Innovative Medicines to Patients Faster

Multinational Corporations

Bristol Myers Squibb™
Vidaza, Revlimid

AMGEN®
BLINCYTO, KYPROLIS, XGEVA

NOVARTIS
Taflinar, Mekinist, Votrient, Affinitor, Zykadia
Tislelizumab, Ociperlimab

Small and Mid-sized Companies

assemblybio
Vebicorvir

百奥泰 BIO-THERA

BITT

EUSAPharma
Acquired by Recordati (2021)
Qarziba, Sylvant

HUTCHMED

leaptherapeutics
anti-DKK1

Leads Biolabs
anti-LAG-3

MEI Pharma

MIRATI THERAPEUTICS
Sitravatinib

Mapkure
JV with SpringWorks

SpringWorks THERAPEUTICS

Seagen®
anti-CD70nt

zymeworks
Zanidatamab, ZW49

Access to Innovation

SHORELINE biosciences
Entry into cell therapy with iPSC-derived NK CAR

STRAND THERAPEUTICS
Entry into mRNA therapeutics

INNOVENT 深信生物
Entry into LNP therapeutics

Clinical Supply Agreements for Combination

Abbisko 和誉

Asieris

德琪医药 ANTENGENE

微芯生物 CHIPSCREEN

Gopherwood Biotech

HARBOUR BIOMED

IMMiX Biopharma

IMMUNE-ONC therapeutics

Prelude THERAPEUTICS

Phanes Therapeutics

PURETECH

Simcere

TiUM BIO

BeiGene

Building State-of-the-Art Manufacturing to Support Global Growth and Broad Portfolio

Multi-Functional Manufacturing Facility in Suzhou

- Aligned with the design criteria of U.S., EU, and China
- Commercial-scale small molecule drug products facility
- Pilot-scale biologic facility

Experienced, High-Quality Manufacturing Partners

Boehringer Ingelheim

Catalent

- Manufacturing collaborations with leading manufacturers in biologics and small molecules

Biologics Manufacturing Facility in Guangzhou

- Approved capacity 16,000L
- 54,000L completed in 2022 + 10,000L in Q2 2023
- Building to 200,000L

Future U.S. Manufacturing Facility at the Princeton West Innovation Center, NJ

- Construction underway on a U.S. manufacturing site for biologic manufacturing and clinical development – complete by 1H 2024
- 1 million+ sq ft of space for future expansion

BeiGene became the first company to have two sites approved in China for a biologic product (tislelizumab)

2023 Milestones and Catalysts

*U.S. FDA pre-approval manufacturing inspections for tislelizumab biologics license application (BLA) scheduled for completion by end of Q2

BeiGene

2023 Milestones and Catalysts (cont'd)

		1H 2023	2H 2023
BGB-11417 (BCL-2)	Study progress		Initiate global pivotal trial in 1L CLL in combo with BRUKINSA
	Data readout		Data readouts from ongoing studies
Ociperlimab (anti-TIGIT Ab)	Data readout	Readouts for multiple P2 studies, including: 2L ESCC in patients whose tumors express PD-(L)1, 1L HCC and 1L NSCLC	
	Study progress	Complete enrollment in Ph3 AdvanTIG 302 in 1L NSCLC	
BGB-16673 (BTK Degrader)	Data readout	Initial data readout from Phase I study in B cell malignancies	
BGB-A445 (anti-OX40)	Data readout	Initial data readout for Phase 1 study in solid tumors	
BGB-15025 (HPK1 inhibitor)	Data readout	Initiate dose expansion in combination with tislelizumab in solid tumors	
LBL-007 (anti-LAG-3)	Study progress	Initiate patient dosing + tislelizumab in umbrella studies	
Additional Early Programs	Study progress	Initiate 15 novel IO combos across 6 trials with tislelizumab including LAG3, OX40, TIM3, TIGIT, and HPK1, targeting multiple new tumor types including HNSCC, CRC, UBC, RCC, melanoma	

Key Takeaways

1. BeiGene's transformational next-generation model is leveraging unique global opportunities created by worldwide industry changes.

2. We are building a global ecosystem of innovation, cost, and speed competitive advantages that are designed to outperform key success indicators heralded by our evolving industry.

3. We fight for life against cancer —internally and with partners— in the unrelenting pursuit for exceptional science, quality, and impact by cost-effectively driving global operational excellence.

4. We aspire to deliver improved medicines to more patients around the world, more affordably.

Thank you

Appendix slides follow

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. GAAP)

(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

	Three Months Ended March 31,	
	2023	2022 [1]
	(Unaudited)	
Revenue:		
Product revenue, net	$ 410,291	$ 261,573
Collaboration revenue	37,510	45,053
Total revenues	447,801	306,626
Expenses:		
Cost of sales - products	81,789	65,237
Research and development	408,584	389,915
Selling, general and administrative	328,499	294,573
Amortization of intangible assets	187	188
Total expenses	819,059	749,913
Loss from operations	(371,258)	(443,287)
Interest income (expense), net	16,016	10,071
Other (loss) income, net	18,303	11,967
Loss before income taxes	(336,939)	(421,249)
Income tax expense	11,492	13,949
Net loss	(348,431)	(435,198)
Net loss per share attributable to BeiGene, Ltd.:		
Basic and diluted	$ (0.26)	$ (0.33)
Weighted-average shares outstanding:		
Basic and diluted	1,354,164,760	1,332,017,262
Net loss per ADS attributable to BeiGene, Ltd.:		
Basic and diluted	$ (3.34)	$ (4.25)
Weighted-average ADSs outstanding:		
Basic and diluted	104,166,520	102,462,866

1.We revised certain prior period financial statements for an error related to the valuation of net deferred tax assets, the impact of which was immaterial to our previously filed financial statements in the first and second quarters of 2022 (see "Notes to the Condensed Consolidated Financial Statements, Note 1. Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies" and "Note 2. Revision of Prior Period Financial Statements" included in our Quarterly Report on Form 10-Q for the period ended March 31, 2023 filed with the SEC).

Our Commitment to ESG

Our global strategy is focused on five areas supported by ten strategic priorities.

We have shared our progress against our 2022 targets and announce new goals in our 2022 ESG Report, which was published in April.

OUR PROGRESS

BeiGene made substantial progress in 2022 across all five Change Is the Cure focus areas and set a number of new goals.

Focus Area	2022 Goals	2022 Progress	New Goals
Advancing Global Health	■ Continue to invest in medicines across multiple modalities with 10 new molecules in clinic between 2022-2023	✓ Complete. Entered three new molecules in clinic	☐ 10 new molecules in clinic annually beginning in 2024
	■ Continue to seek approvals for our medicines globally	✓ Complete. BRUKINSA approved in 19 new countries and regions in 2022	
	■ Define pricing principles and affordability strategy	✓ Complete. Published BeiGene's Position on Affordability	
Empowering Our People	■ Improve colleague engagement by three percent globally versus 2020 engagement scores	✓ Complete. Improved by 7%	☐ Maintain colleague engagement scores globally versus 2022 engagement scores with a stretch goal of +3% for the 2024 engagement survey ☐ Improve work-life balance survey scores by 3%, with a stretch goal of 5% in 2023 **By 2030:** ☐ Reach global gender parity at the VP level and above ☐ Achieve a 50% improvement in workforce diversity (underrepresented groups) company-wide at management levels in the U.S. ☐ Continue to address the composition of the Board of Directors for gender and U.S. underrepresented groups
	■ Roll out a global initiative to address work-life balance	✓ Complete. Rolling out a leadership-driven behavior change program to improve work-life balance	
	■ Develop a three-year global strategy to improve DEI&B across the company	✓ Complete. 2030 goals approved by Board of Directors	

OUR PROGRESS (CONT'D)

BeiGene made substantial progress in 2022 across all five Change Is the Cure focus areas and set a number of new goals.

Focus Area	2022 Goals	2022 Progress	New Goals
Innovating Sustainably	■ Achieve ISO 14001 certifications for our Suzhou and Guangzhou manufacturing facilities	✓ Complete. Certification for each facility received in November 2022	☐ Set a quantitative Scopes 1 and 2 emissions goal by 2024 ☐ Set a quantitative Scope 3 emissions goal by 2025. To advance this goal, engage with two-thirds of our raw material supplier base (based on 2021 spend information) ☐ Continued from 2022: Explore the creation of a product stewardship program (This goal is in progress as we continue to evaluate internal product stewardship efforts.)
	■ Expand GHG inventory to include Scope 3 emissions	✓ Complete. Inventory compiled	
	■ Conduct a climate risk scenario analysis and assessment aligned with the Task Force for Climate-Related Financial Disclosures (TCFD) recommendations	✓ Complete. TCFD-aligned climate risk scenario analysis and assessment completed	
	■ Set a global climate strategy	✓ Complete. Strategy developed	
Supporting Communities	■ Develop a three-year patient engagement and advocacy strategy	✓ Complete. Strategy developed	☐ Spearhead multi-stakeholder solutions that empower patients and disrupt systemic access barriers by 2025 ☐ Engage employees in 10,000 hours of global volunteerism by 2023 ☐ Expand paid volunteer time-off policy globally in 2023
	■ Expand partnerships and collaborations with organizations around the world focused on health policy, equity, and patient needs	✓ Complete. Launched Talk About It: Cancer and Mental Health	
	■ Launch colleague engagement and volunteer events in the U.S., Europe, and Australia	✓ Complete. Piloted a paid volunteer time-off policy in the U.S.; organized colleague engagement events in U.S., Europe, Australia, and China	
	■ Engage employees to support organizations focused on cancer awareness raising, patient support, and research	✓ Complete. Employees participated in numerous events to support patient organizations	
Operating Responsibly	■ Become a signatory of the UN Global Compact	✓ Complete. Joined in May 2022 ✓ Participating in the UN Global Compact's SDG Ambition Accelerator	☐ Continued from 2022: Implement a third-party supplier risk management program in 2023 (Manager hired in 2022 to oversee development and implementation)